Prognostic and Clinical Pathological Significance of the Systemic Immune-inflammation Index in Urothelial Carcinoma: a Systematic Review and Meta-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Apr 10

PMID 38595827

Authors

Yao Wang

Xiaoming Hao

Gang Li

Affiliations

Soon will be listed here.

Abstract

Background: A new non-invasive biomarker, the Systemic Immune-Inflammation Index (SII), has been proven to have prognostic value in multiple cancers. This systematic review and meta-analysis aimed to investigate the prognostic and clinical pathological significance of SII in urothelial carcinoma.

Methods: A comprehensive search was conducted across multiple databases, including PubMed, Web of Science, Embase, Cochrane Library, and CNKI. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Hazard ratios (HR) with 95% confidence intervals (CI) were calculated to evaluate the prognostic value of SII before treatment on survival outcomes, and odds ratios (OR) with 95%CI were used to assess the correlation between SII before treatment and clinical pathological features.

Results: This meta-analysis included a total of 10 studies (11 datasets) with 6,333 patients. The pooled analysis showed that high SII before surgery was significantly associated with poor survival outcomes in patients with urothelial carcinoma, including overall survival (OS) (HR=1.55, 95%CI 1.24-1.95, p<0.001), cancer-specific survival (CSS) (HR=2.74, 95%CI 1.67-4.49, p<0.001), recurrence-free survival (RFS) (HR=2.74, 95%CI 1.67-4.49, p<0.001), and progression-free survival (PFS) (HR=1.66, 95%CI 1.36-2.02, p<0.001). In addition, patients with elevated preoperative SII values were more likely to have adverse pathological features, including larger tumor size and advanced pathological T stage (p<0.001).

Conclusion: These findings suggest a significant association between high SII levels before treatment and poor survival outcomes, as well as certain clinical pathological features, in patients with urothelial carcinoma.

Citing Articles

Prognostic scores for predicting overall survival in patients with metastatic renal and urothelial cancer undergoing immunotherapy - which one to use?.

Walach M, Burger R, Brumm F, Nitschke K, Wessels F, Nuhn P World J Urol. 2025; 43(1):93.

PMID: 39880915 PMC: 11779752. DOI: 10.1007/s00345-025-05452-4.

The role of systemic immune-inflammation index in predicting pathological complete response of breast cancer after neoadjuvant therapy and the establishment of related predictive model.

Zhang Z, Zeng Y, Liu W Front Oncol. 2024; 14:1437140.

PMID: 39555449 PMC: 11564179. DOI: 10.3389/fonc.2024.1437140.

References

Gonzalez H, Hagerling C, Werb Z . Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20):1267-1284. PMC: 6169832. DOI: 10.1101/gad.314617.118. View

Roupret M, Seisen T, Birtle A, Capoun O, Comperat E, Dominguez-Escrig J . European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol. 2023; 84(1):49-64. DOI: 10.1016/j.eururo.2023.03.013. View

Jin M, Yuan S, Yuan Y, Yi L . Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis. Front Oncol. 2021; 11:735803. PMC: 8689141. DOI: 10.3389/fonc.2021.735803. View

Mori K, Resch I, Miura N, Laukhtina E, Schuettfort V, Pradere B . Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. Cancer Immunol Immunother. 2021; 70(9):2641-2650. PMC: 8360829. DOI: 10.1007/s00262-021-02884-w. View

Atasever Akkas E, Yucel B . Prognostic value of systemic ımmune ınflammation ındex in patients with laryngeal cancer. Eur Arch Otorhinolaryngol. 2021; 278(6):1945-1955. DOI: 10.1007/s00405-021-06798-2. View

Grisaru-Tal S, Dulberg S, Beck L, Zhang C, Itan M, Hediyeh-Zadeh S . Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity. Cancer Res. 2021; 81(21):5555-5571. DOI: 10.1158/0008-5472.CAN-21-0839. View

Palacka P, Slopovsky J, Obertova J, Chovanec M, Rejlekova K, Sycova-Mila Z . Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC). Anticancer Res. 2021; 41(11):5749-5759. DOI: 10.21873/anticanres.15391. View

Zheng Y, Yu D, Yu Z, Zhao D, Chen Y, Chen W . Association of preoperative systemic Immune-inflammation Index and Prognostic Nutritional Index with survival in patients with Upper Tract Urothelial Carcinoma. J Cancer. 2020; 11(19):5665-5677. PMC: 7477451. DOI: 10.7150/jca.44915. View

Hu C, Bai Y, Li J, Zhang G, Yang L, Bi C . Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer. BMC Urol. 2020; 20(1):57. PMC: 7251912. DOI: 10.1186/s12894-020-00628-z. View

10.

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

11.

Adam J, Odhav B, Bhoola K . Immune responses in cancer. Pharmacol Ther. 2003; 99(1):113-32. DOI: 10.1016/s0163-7258(03)00056-1. View

12.

Gaertner F, Massberg S . Patrolling the vascular borders: platelets in immunity to infection and cancer. Nat Rev Immunol. 2019; 19(12):747-760. DOI: 10.1038/s41577-019-0202-z. View

13.

Fornarini G, Rebuzzi S, Banna G, Calabro F, Scandurra G, De Giorgi U . Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open. 2021; 6(3):100118. PMC: 8134706. DOI: 10.1016/j.esmoop.2021.100118. View

14.

Gakis G, Witjes J, Comperat E, Cowan N, De Santis M, Lebret T . EAU guidelines on primary urethral carcinoma. Eur Urol. 2013; 64(5):823-30. DOI: 10.1016/j.eururo.2013.03.044. View

15.

Hirahara N, Tajima Y, Matsubara T, Fujii Y, Kaji S, Kawabata Y . Systemic Immune-Inflammation Index Predicts Overall Survival in Patients with Gastric Cancer: a Propensity Score-Matched Analysis. J Gastrointest Surg. 2020; 25(5):1124-1133. DOI: 10.1007/s11605-020-04710-7. View

16.

Man Y, Stojadinovic A, Mason J, Avital I, Bilchik A, Bruecher B . Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer. 2013; 4(1):84-95. PMC: 3564249. DOI: 10.7150/jca.5482. View

17.

Soria F, Shariat S, Lerner S, Fritsche H, Rink M, Kassouf W . Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2016; 35(3):379-387. DOI: 10.1007/s00345-016-1928-x. View

18.

Yang C, Hu B, Tang F, Zhang Q, Quan W, Wang J . Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: A Comprehensive Study Based on Meta-Analysis and Retrospective Single-Center Analysis. J Clin Med. 2022; 11(24). PMC: 9787672. DOI: 10.3390/jcm11247514. View

19.

Chen Y, Shao G, Li J, Yang A, Li J, Ye X . O-GlcNAcylation of Blimp-1 in Lymphocytes Inhibits Its Transcriptional Function and Is Associated with Migration and Invasion of Breast Cancer Cells. Mol Cancer Res. 2021; 20(4):650-660. DOI: 10.1158/1541-7786.MCR-21-0405. View

20.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View